Jubilant Ingrevia share price today

Jubilant Ingrevia Ltd's share price was ₹572.40 at the close on 6 November 2026. It has been falling for 3 weeks. That is 14.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹558 and ₹743, and at that close it sat 8% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Jubilant Ingrevia Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running.

Over the last 5.6 years the share price moved +113% while the NIFTY 500 moved +80%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 28 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: indian funds and insurers (DIIs) raised their stake for 6 quarters in a row, highest quarterly profit in 16 quarters and highest quarterly revenue in 16 quarters.

1. Indian funds and insurers (DIIs) raised their stake for 6 quarters in a row

   From 15.9% to 25.2% of the company by the September 2026 quarter.

2. Highest quarterly profit in 16 quarters

   Profit of ₹111 crore in the September 2026 quarter is the highest of the last 16 quarters.

   Why: Profit rose because chemical intermediates made more from better product prices, and stronger premix prices helped nutrition.

   Next results: check whether weak animal feed B3 prices continue into the third quarter and hurt the share of sales the company keeps as profit.

   From the earnings call on 27 Oct 2026.

3. Highest quarterly revenue in 16 quarters

   Revenue of ₹1,394 crore in the September 2026 quarter is the highest of the last 16 quarters.

   Why: Revenue rose because specialty chemicals did more business in fine chemicals and CDMO across agro, pharma, personal care and semiconductors.

   Next results: check whether the large CDMO customer gives clear future volumes and contract length.

   From the earnings call on 27 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Jubilant Ingrevia reported revenue of ₹1,394 crore, up 24.4% from ₹1,121 crore a year earlier, and a profit of ₹111 crore, up 60.9% from ₹69.0 crore.

Jubilant Ingrevia results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Jubilant Ingrevia's management discussed these results on a call held on 27 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Jubilant Ingrevia closed at ₹572.40 on 6 November 2026, down 12.6% from ₹654.80 a year earlier (7 November 2025) and down 10.0% over five years. Its highest weekly close since March 2021 was ₹859.20 on 3 January 2025.

Jubilant Ingrevia share price: then and now

Weekly closing prices. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

301 weekly closes from 19 March 2021 to 6 November 2026.

6 Nov 2026: Jubilant Ingrevia closed at ₹572.40, up 2.5% on the week and down 8.5% on the month. 27 Oct 2026: Jubilant Ingrevia held its results call for July to September 2026. Management guided: FY27 annual guidance of ₹750-800 crore reaffirmed, with performance expected closer to the upper end on H1 strength.

Earlier

• Results for July to September 2026: Revenue up 24.4% and profit up 60.9% on a year earlier.
• 24 Jul 2026: ex-date for a dividend of ₹2.50 a share.
• 10 Feb 2026: ex-date for an interim dividend of ₹2.50 a share.

Jubilant Ingrevia paid ₹5 a share in regular dividends in the 12 months to 7 November 2026 (2 payments), a yield of 0.87% at the ₹572.40 close on 6 November 2026. The last was a dividend of ₹2.50 a share, ex-date 24 July 2026.

Jubilant Ingrevia dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Jubilant Ingrevia Ltd paid out 28% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 7 reported years.

From the NSE corporate-actions record, read 7 November 2026.

On the call for July to September 2026, held on 27 October 2026, Jubilant Ingrevia's management guided: FY27 annual guidance of ₹750-800 crore reaffirmed, with performance expected closer to the upper end on H1 strength.

“Our quarterly EBITDA has more than doubled over the past 3 years, underscoring the successful execution of our Pinnacle strategy and our continued focus on disciplined cost management.”Shyam Bhartia, on the call for July to September 2026

What management guided

• FY27 growth expected across all segments; Acetyls closure uplift starts early CY27, with larger FY28 potential and market-share doubling over a couple of years if the plant remains shut.
• At least one-third of the ₹1,500 crore-plus peak potential from confirmed CDMO opportunities, excluding the large contract, to be booked in FY27.
• Specialty Chemicals portfolio growth aspiration of 20%-25% on a multi-year yearly growth basis; quarterly performance may be lumpy.
• ZettaOne FY27 growth expected at 60%-70%, potentially higher.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 27 October 2026.

When Jubilant Ingrevia reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Large CDMO customer scenarios: check whether future volumes and contract duration become visible by the next call.

Jubilant Ingrevia is on one of our India lists: 52 week high & low.

Jubilant Ingrevia Ltd earned ₹111 Cr of net profit in the Sep 2026 quarter, +60.9% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹278 Cr. That is 8.0% of the quarter's revenue. The same quarter a year earlier earned ₹69.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹278 Cr (+10.8% on the year before).

Why profit moved: revenue changed +24.4% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +21.6% and revenue +15.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

FY26-Q4. Revenue 1179 cr, PAT 86 cr, OPM 13.8%, this review produced no quarter-level why; see the levers.

FY27-Q1. Revenue 1300 cr, PAT 106 cr, OPM 15.3%, this review produced no quarter-level why; see the levers.

Why-sources: our stock research file (6 September 2026) and the company’s own results for those quarters.

Jubilant Ingrevia Ltd reported ₹1,394 Cr of revenue in the Sep 2026 quarter, +24.4% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. The last full year, FY26, came in at ₹4,388 Cr. The last four reported quarters add to ₹4,924 Cr.

Revenue is everything the company billed its customers in the period.

A growth rate over several years is not shown, because there are too few years of figures to work one out properly.

FY26 revenue was ₹4,388 Cr, +5.0% on the year before.

Is growth speeding up? Revenue over the last 12 months grew +15.4%, against +9.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +22.0%, against +41.0% a year (rolling over).

FY26-Q4. Revenue 1179 cr, PAT 86 cr, OPM 13.8%, this review produced no quarter-level why; see the levers.

FY27-Q1. Revenue 1300 cr, PAT 106 cr, OPM 15.3%, this review produced no quarter-level why; see the levers.

Why-sources: our stock research file (6 September 2026) and the company’s own results for those quarters.

Jubilant Ingrevia Ltd's operating margin was 15.0% in the Sep 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 6 years it has been between 10.0% and 17.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +3.2 percentage points on the year while gross margin changed +2.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY26-Q4. Revenue 1179 cr, PAT 86 cr, OPM 13.8%, this review produced no quarter-level why; see the levers.

FY27-Q1. Revenue 1300 cr, PAT 106 cr, OPM 15.3%, this review produced no quarter-level why; see the levers.

Why-sources: our stock research file (6 September 2026) and the company’s own results for those quarters.

Over the last 3 years, 205% of Jubilant Ingrevia Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹524 Cr of operating cash against ₹278 Cr of profit. After ₹406 Cr of spending on assets, ₹118 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 205% of profit came in as cash: the cash cycle got 112 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 3.1× depreciation over three years. The next section checks what that spending is building.

Jubilant Ingrevia Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 55 days in FY26, down from 167 days in FY21. It spent ₹1,435 Cr on assets over the last 3 years. Customers take 65 days to pay, and stock sits for 140 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹4,388 Cr, each day of that cycle ties up about ₹12.0 Cr, so roughly ₹661 Cr is tied up in the business at any time.

FY26: customers took 65 days to pay and stock sat for 140 days, about 4.6 months of sales sitting as stock, for a full cycle of 55 days, shorter than FY21's 167.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 140 days. Customers pay about 65 days after that. Suppliers are paid at 150 days. Together that makes the 55-day cycle.

Spending on assets: ₹1,435 Cr over the last 3 years, against ₹469 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹154 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Jubilant Ingrevia Ltd's P/E is 25.3×, near the low end of its own history: it has been lower only 29% of the time. Its usual P/E (the middle reading) is 36.5×, over 5.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹22.01.

Why the multiple is where it is: over the past year earnings per share moved +10.7% while the price moved −12.6%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 5 years the price moved −2.1% a year; about +41.5% a year came from earnings growth and about −43.6 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Jubilant Ingrevia Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE rising at 13.5%; each line tells part of the story. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Jubilant Ingrevia Ltd's story is not scored yet against the checks our research set on 6 September 2026. Where it sits in its own cycle: mixed. Checks so far: 12 not due yet.

NOT YET CHECKED 12 not due yet · first check at the next results

The test written in advance. Large CDMO contract quarterly volumes and EBITDA contribution (company disclosure), Another pause, a make-whole invocation, or continued 'no firm timeline'. Measured by: Large CDMO contract quarterly volumes and EBITDA contribution (company disclosure) Q1 FY27: partial volumes, EBITDA-positive but unquantified; innovator paused part of the volume by FY27-Q2 (call expected late Oct 2026).

The test written in advance. FY27 EBITDA guidance of Rs 750-800 crore (quarterly run-rate), Quarters well below Rs 200cr, forcing the guide off the 800 end. Measured by: FY27 EBITDA guidance of Rs 750-800 crore (quarterly run-rate) Q1 FY27 EBITDA Rs 209cr; H1 expected around Rs 400cr-plus, roughly Rs 200cr per quarter (Varun Gupta) by Each quarter through FY27-Q4.

The test written in advance. Vitamin B3 / nicotinamide pricing and Nutrition segment EBITDA, China nicotinamide prices reverse the spike and Nutrition EBITDA falls back toward the Rs 23-25cr range of Q3 FY26. Measured by: Vitamin B3 / nicotinamide pricing and Nutrition segment EBITDA by FY27-Q2 and FY27-Q3.

• 1 · Operating leveragebuilding
• 2 · Value-added mixbuilding
• 3 · Management changequiet
• 4 · Paying down debtworking now
• 5 · Regulatory approvalquiet
• 6 · Order-book winsbuilding
• 7 · Consolidationquiet
• 8 · Demerger or value unlockquiet
• 9 · Buybackquiet
• 10 · New geographiesquiet
• 11 · More business from existing customersquiet
• 12 · New product launchbuilding
• 13 · Mandatory normsquiet
• 14 · A bigger market to servequiet
• 15 · Market-share gainsquiet
• 16 · Asset qualityquiet

Lever 2 · Value-added mix: building. Specialty FY26 revenue Rs 1,937cr (+7%), EBITDA Rs 510cr (+21%); specialty+nutrition 85%+ of EBITDA; Specialty margins 25-27% across six quarters (Q3 FY26 was 25.3%); Nutrition Q1 FY27 EBITDA Rs 36cr at 15%. What proves it keeps working: 'Portfolio mix moving in favor of specialty and nutrition, contributing almost 85% plus of overall EBITDA. Specialty EBITDA almost doubling in last 2 years.' (26 May 2026). It stops working if Q3 FY26 Specialty margin was 25.3% ('above 25%'), not 27%; the 85% share oscillates with the acetyls cycle (87% in Q3 FY25 vs 73% in Q2 FY25) and rose partly because Chemical Intermediates EBITDA fell 39% over 9M FY25 (B2, bear wins).

Lever 6 · Order-book wins: building. $300m over 5 years = $60m a year, close to Rs 500cr annualised; supplies began March 2026; Q1 FY27 partial volumes, EBITDA-positive but unquantified; 25+ confirmed molecules, Rs 3,500cr+ peak-revenue funnel. What proves it keeps working: 'In the unforeseen circumstances of they not giving us any volume, we have full protection, which will more than cover for whatever EBITDA expectations we have communicated to the markets.' (23 July 2026).

Lever 4 · Paying down debt: working now. Net debt/EBITDA 1.36x (Dec 2024) to 0.99x (Mar 2026); derived interest cover 5.49x (Mar 2024) to 8.02x (Mar 2026); derived debt-to-equity 0.2534. What proves it keeps working: 'Net debt by EBITDA improved to 0.99x. Our net debt has reduced by 11% in 2026.' (26 May 2026). It stops working if Gross borrowings rose Rs 740cr to Rs 792cr; the improvement came from cash doubling (Rs 78.8cr to Rs 189.9cr) and EBITDA lifting the denominator, not repayment, but the financial benefit itself stands (B8, bull wins); no operating credit taken.

Sources: our results-season review, 6 September 2026. The story check is re-scored every results season; the record below never changes.

What Jubilant Ingrevia Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Agrochemical Outlook Reversal · 27 October 2026. In May 2026, management described agrochemicals as delivering strong growth with successful price increases, and in Jul 2026 it still cited recovery, export visibility, and recent price increases. In Oct 2026, management instead characterized the segment as under pressure with muted pricing, a material change in the market narrative that affects volume, pricing, and margin assumptions; citing excess capacity in China does not reconcile the reversal with the earlier outlook.

Large CDMO Contract Visibility Timeline Slipped · 27 October 2026. May 2026 indicated that management expected next-quarter volume visibility by the following month, and Jul 2026 repeated that a way forward would be disclosed within a few weeks. In Oct 2026, management again said it was only very close to concluding the way forward and again pushed disclosure to the next few weeks, without explaining why the earlier timelines were missed; this remains material to Specialty Chemicals forecasting.

Full-Year EBITDA Guidance Framework Changed · 23 July 2026. In May 2026, management explicitly framed the full-year EBITDA outlook as at least 20% growth, following FY26 EBITDA of Rs. 510 crore; the February 2026 call used the same at-least-20% multiyear framework. In Jul 2026, management referred to full-year guidance of 750 to 800 crores, which implies roughly 47%-57% growth over FY26 EBITDA, a material step-up that was not reconciled with the prior call guidance. Management attributed the range to an intervening Bharuch discussion, but did not explain the change in the provided calls.

Major CDMO Contract Volume Certainty · 26 May 2026. In the Oct 2025 call, management expressed absolute certainty regarding the volume ramp of their $300 million major agro innovator contract, claiming it would run at 100% potential from the very first day. However, in the May 2026 call, management revealed that the customer is facing financial difficulties and the future volume scenarios are suddenly unclear, forcing them to rely on contractual "make whole" defensive clauses rather than guaranteed operational scale.

Every quote above is taken word for word from the company’s own earnings calls.

Jubilant Ingrevia Ltd earned a ROCE of 11% in FY26. That is up from a low of 8% in FY21. Its return on capital used (ROIC) is 1.7 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a 6.3% net margin and 0.80× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a 6.3% net margin × 0.80× asset turnover × 1.75× leverage (assets divided by equity) ≈ 8.8% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 10.3% − 12.0% = −1.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 10.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 8.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Jubilant Ingrevia Ltd has total debt of ₹895 Cr against shareholder equity of ₹3,316 Cr as of Sep 2026, so its debt is 0.27× its equity, which is very little. Year by year, that ratio went from 0.10 in FY22 to 0.25 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions raised their stake in Jubilant Ingrevia Ltd by 9.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 25.2% of the company. Promoters moved −6.3 points over the same period, to 45.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: +9.7 points over 8 quarters, to 25.2%; Promoters: −6.3 points over 8 quarters, to 45.2%; Foreign institutions: −0.3 points over 8 quarters, to 6.9%.

Why the owners changed: domestic institutions drove it (+9.7 points), with the other side taken by promoters (−6.3 points). They raised their stake step by step.

For Jubilant Ingrevia Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

54.7 out of 100, rank 9 of 25 in Pesticides/Agrochemicals, with 93% of the evidence available.

Jubilant Ingrevia Ltd scores 54.7 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 9. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 26 + 13.6 + 6.7 + 8.4 = 54.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Jubilant Ingrevia ranks 9 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 54.7 out of 100.